**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

SCHEDULE 13G\*

(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT**

**TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED**

**PURSUANT TO RULE 13d-2**

**(Amendment No. \_\_\_)\***

Y-mAbs Therapeutics, Inc.



(Name of Issuer)

Common Stock



(Title of Class of Securities)

984241109



(CUSIP Number)

August 24, 2018



(Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

* Rule 13d-1(b) ☒ Rule 13d-1(c)
* Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).



CUSIP NO. 984241109



**13G**

Page 2 of 5 Pages



|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1. |  | NAME OF REPORTING PERSONS |  |  |
|  |  |  | Nai-Kong V. Cheung |  |  |
|  |  |  |  |  |
| 2. |  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |  |  |
|  |  | (see instructions) | (a) | ☐ |  |
|  |  |  |  |  |
|  |  |  |  | (b) | ☐ |  |
|  |  |  |  |  |  |
| 3. |  | SEC USE ONLY |  |  |  |
|  |  |  |  |  |
| 4. |  | CITIZENSHIP OR PLACE OF ORGANIZATION United States |  |  |
|  |  |  |  |  |  |  |
|  |  |  | 5. | SOLE VOTING POWER |  |  |
|  |  |  |  | 2,426,400 |  |  |
| NUMBER OF | 6. | SHARED VOTING POWER |  |  |
| SHARES |  |  |
|  |  |  |  |
| BENEFICIALLY |  |  |  |  |
| OWNED BY |  |  |  |  |
|  | EACH | 7. | SOLE DISPOSITIVE POWER |  |  |
| REPORTING |  |  |
|  | 2,426,400 |  |  |
| PERSON |  |  |  |
|  |  |  |  |
|  | WITH | 8. | SHARED DISPOSITIVE POWER |  |  |
|  |  |  |  |  |
|  |  |  |  |  |  |
| 9. |  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,426,400 |  |  |
|  |  |  |  |  |  |
| 10. |  | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES |  |  |
|  |  | CERTAIN SHARES ☐ |  |  |
| 11. |  | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.64% |  |  |
|  |  |  |  |  |  |
| 12. |  | TYPE OF REPORTING PERSON (See Instructions) IN |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |



CUSIP NO. 984241109



**13G**

Page 3 of 5 Pages



**Item 1(a).** **Name of Issuer:** Y-mAbs Therapeutics, Inc.

**Item 1(b).** **Address of Issuer’s Principal Executive Offices:** 230 Park Avenue, Suite 3350, New York, NY 10169

**Item 2(a).** **Name of Person Filing:** Nai-Kong V. Cheung

**Item 2(b).** **Address of Principal Business Office or, if none, Residence:** 425 E. 58thSt., Apt 34D, New York, NY 10022

**Item 2(c).** **Citizenship:** United States

**Item 2(d).** **Title of Class of Securities:** Common Stock

**Item 2(e).** **CUSIP Number:** 984241109

**Item 3.** **If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:**

1. ☐Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
2. ☐Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
3. ☐Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
4. ☐Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
5. ☐An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
6. ☐An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
7. ☐A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
8. ☐A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
9. ☐A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
10. ☐A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
11. ☐Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_



CUSIP NO. 984241109



**13G**

Page 4 of 5 Pages



**Item 4.** **Ownership:**

Provide the following information regarding the aggregate number and percentage of class of securities of the issuer identified in Item 1.

1. Amount beneficially owned: 2,426,400
2. Percent of Class: 8.64%
3. Number of shares as to which such person has:
	1. sole power to vote or to direct the vote: 2,426,400
	2. shared power to vote or to direct the vote:
	3. sole power to dispose or to direct the disposition of: 2,426,400
	4. shared power to dispose or to direct the disposition of:

**Item 5.** **Ownership of Five Percent or Less of a Class:**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

**Item 6.** **Ownership of More than Five Percent on Behalf of Another Person: N/A**

**Item 7.** **Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: N/A**

**Item 8.** **Identification and Classification of Members of the Group: N/A**

**Item 9.** **Notice of Dissolution of Group: N/A**



CUSIP NO. 984241109



**Item 10.** **Certifications:**

**13G**

**SIGNATURE**

Page 5 of 5 Pages



After reasonable inquiry and to the best of its knowledge and belief, I certify (the undersigned certifies) that the information set forth in this statement is true, complete and correct.

8/25/2020



(Date)

/s/ Nai-Kong V. Cheung



(Signature)

Nai-Kong V. Cheung



Name and Title

